Cybrexa is a clinical-stage oncology biotechnology company developing novel antigen-independent peptide drug conjugates (ADCs) aimed at combatting a range of cancer types, including ovarian, breast and non-small cell lung cancer. With the potential to disrupt the standard of care, the Cybrexa alphalex™ technology is a novel antigen-independent peptide drug conjugate (PDC) platform that enables targeted delivery of highly potent anticancer treatments and aims to revolutionize the standard of care in oncology. The platform consists of a pHLIP® peptide, linker, and small molecule anti-cancer agent. pHLIP® peptides are a family of pH-Low Insertion Peptides that target acidic cell surfaces. pHLIP® was developed at Yale University and the University of Rhode Island, and is exclusively licensed to pHLIP, Inc. alphalex™ represents the disruptive next generation in tumor targeting. Early clinical trials of the company’s lead candidate, CBX-12, demonstrate robust efficacy signals and tolerability in patients with metastatic cancer. As a privately held company, Cybrexa is led by a management team experienced at building life science companies and driven by scientists with an expertise in drug development and oncology. For more information, visit www.cybrexa.com. Community Guidelines: https://bit.ly/3GI6AU0
View Top Employees from Cybrexa TherapeuticsWebsite | http://www.cybrexa.com |
Revenue | $5.3 million |
Employees | 21 (21 on RocketReach) |
Founded | 2017 |
Address | 5 Science Park, New Haven, Connecticut 06511, US |
Phone | (860) 717-2731 |
Technologies |
JavaScript,
HTML,
PHP
+20 more
(view full list)
|
Industry | Biotechnology Research, Education General, Biotechnology, Education, Science and Engineering, Pharmaceutical, Health Care, Therapeutics |
Web Rank | 17 Million |
Keywords | Cybrexa Therapeutics, Cybrexa, Cybrexa Jobs |
Competitors | Cellectar Biosciences, Inc., DelMar Pharmaceuticals, InteRNA Technologies BV, Step Pharma, TYME Technologies Inc. |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 541714 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies |
Looking for a particular Cybrexa Therapeutics employee's phone or email?
The Cybrexa Therapeutics annual revenue was $5.3 million in 2024.
Rob Maguire is the Director Of Chemistry of Cybrexa Therapeutics.
21 people are employed at Cybrexa Therapeutics.
Cybrexa Therapeutics is based in New Haven, Connecticut.
The NAICS codes for Cybrexa Therapeutics are [541, 54171, 541714, 54, 5417].
The SIC codes for Cybrexa Therapeutics are [87, 873].